Pulmorphix has developed the world’s first lung biosimulator device to allow investigation of dissolution behaviour of orally inhaled products (OIPs). The biosimulator mimics lung conditions allowing analysts in the pharmaceutical industry to examine the initial interaction of their formulations with the lung lining fluids under “real life”